Imugene (IMU) Q1 2026 TU earnings summary

Executive summary

• Phase 1b clinical trial of azer-cel in relapsed/refractory DLBCL achieved an 81% overall response rate, with 13 of 16 patients responding, including 7 complete and 6 partial responses.

• Responses to azer-cel have been rapid (1–3 months) and durable, with some patients remaining cancer-free for over 18 months.

• The trial expanded to include CAR T naïve patients with various lymphomas, showing an 83% response rate in this group.

• Internal portfolio review led to a focus on programs with near-term milestones and exploring partnerships for CF33 and onCARlytics.

Financial highlights

• $24.9 million raised via institutional placement and share purchase plan, priced at $0.33 per share.

• $5.87 million R&D tax refund received in July 2025.

• Cash and cash equivalents at quarter end totaled $32.4 million.

• Net cash used in operating activities was $12.57 million, a 3% reduction from the previous quarter.

• Direct R&D expenses accounted for 77% of total operating costs.

Outlook and guidance

• Capital raised will fund azer-cel through initiation of a pivotal clinical trial in 2026 and extend funding runway into mid-2027.

• Enrolment in CAR T naïve cohort is progressing faster, supporting a potential expedited clinical path.